47 results on '"Bogacka E"'
Search Results
2. Allergie oculaire : reconnaître et diagnostiquer les réactions d’hypersensibilité de la surface oculaire
- Author
-
Leonardi, A., Bogacka, E., Fauquert, J.-L., Kowalski, M.-L., Groblewska, A., Jedrzejczak-Czechowicz, M., Doan, S., Marmouz, F., Demoly, P., and Delgado, L.
- Published
- 2014
- Full Text
- View/download PDF
3. Allergie et surface oculaire chez le sujet âgé
- Author
-
Bogacka, E. and Groblewska, A.
- Published
- 2010
- Full Text
- View/download PDF
4. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface
- Author
-
Leonardi, A., Bogacka, E., Fauquert, J. L., Kowalski, M. L., Groblewska, A., Jedrzejczak-Czechowicz, M., Doan, S., Marmouz, F., Demoly, P., and Delgado, L.
- Published
- 2012
- Full Text
- View/download PDF
5. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study
- Author
-
Zuberbier, T., Oanta, A., Bogacka, E., Medina, I., Wesel, F., Uhl, P., Antépara, I., Jáuregui, I., and Valiente, R.
- Published
- 2010
- Full Text
- View/download PDF
6. Investigating patterns of millennials interest in gluten-free beer in Poland: a question of beer price and alcohol content.
- Author
-
Donadini, G., Bertuzzi, Terenzio, KORDIALIK-BOGACKA, E, Rossi, Filippo, Spigno, Giorgia, Porretta, Sebastiano, BERTUZZI T. (ORCID:0000-0003-2235-6991), ROSSI F. (ORCID:0000-0002-0313-4210), SPIGNO G. (ORCID:0000-0003-1636-6851), PORRETTA S., Donadini, G., Bertuzzi, Terenzio, KORDIALIK-BOGACKA, E, Rossi, Filippo, Spigno, Giorgia, Porretta, Sebastiano, BERTUZZI T. (ORCID:0000-0003-2235-6991), ROSSI F. (ORCID:0000-0002-0313-4210), SPIGNO G. (ORCID:0000-0003-1636-6851), and PORRETTA S.
- Abstract
The quality perception of gluten-free beer was explored using conjoint analysis with a panel of Polish millennials (n = 200; aged 20 to 35), who were given 64 gluten-free beer concepts to evaluate and score on a 9-point scale of interest (1 = not interested at all; 9 = extremely interested). The constituent factors of the beer concepts were alcohol content, color, type of malt, price, drinking location and occasion, bottle size, label claims, type of farming, type of brewer, and bottle closure. Consumers judged price (38.4%) and alcohol (28.8%) five times more important than the other factors. Bottle size (5.3%), claims (4.8%), type of brewer (4.8%), malt type (4.6%), bottle closure (4.0%), beer color (3.6%), drinking location (2.3%), drinking occasion (2.0%), and type of farming (1.3%) were considered of little importance. The interest of Polish Millennials in gluten-free beer resulted moderate and not linked to medical needs. Males were more interested in gluten-free beers and gave more importance to alcohol content and less importance to price, compared to females. However, for both genders, interest and price were inversely correlated, while interest and alcohol content were directly correlated.
- Published
- 2020
7. The development of a non-foaming mutant of Saccharomyces cerevisiae
- Author
-
Kordialik-Bogacka, E., primary and Campbell, I., additional
- Published
- 2000
- Full Text
- View/download PDF
8. Skin test with enolase in the diagnosis of fungal allergy
- Author
-
Nittner-Marszalska, M., Kustrzeba-Wójcicka, I., Pisarczyk-Bogacka, E., Medrala, W., and Patkowski, J.
- Published
- 1998
9. SULFIDOLEUKOTRIENE-ELISA ASSAY IN THE DIAGNOSIS OF INSECT ALLERGY: 716
- Author
-
Nittner-Marszalska, M., Malolepszy, J., Bogacka, E., and drala, W. M
- Published
- 1997
10. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
- Author
-
Stempel, Da, Raphiou, Ih, Kral, Km, Yeakey, Am, Emmett, Ah, Prazma, Cm, Buaron, Ks, Pascoe, Sj, Austri, Investigators, Altieri, Hh, Antuni, Jd, Bergna, Ma, Cuadrado, Ja, De Gennaro MS, Fazio Lizandrelo CL, Gattolin, G, Gosn, Am, Larrateguy, Ld, Marcipar, Am, Maspero, Jf, Medina, Iv, Perez Chada RD, Silva, D, Victorio, Cf, Bardin, Pg, Carroll, Pa, Clements, Bs, Dore, Nd, Robinson, Pd, Fitzgerald, Da, Robinson, Pj, Russo, Ma, Sajkov, D, Thomas, Ps, Upham, Jw, Forstner, B, Kaik, G, Koeberl, Gh, Studnicka, M, Wallner, G, Balthazar, Y, Bauler, A, Dupont, Lj, Martinot, Jb, Ninane, V, Peché, R, Pilette, C, Dimitrova, R, Dimova, D, Kissyova Ibrishimova, G, Loboshka Becheva, M, Machkovska, M, Madjarov, S, Mandazhieva Pepelanova, M, Naidenova, I, Noleva, K, Takovska, N, Terziev, C, Aggarwal, Nk, Chapman, Kr, Csanadi, Ma, Dhillon, R, Henein, S, Kelly, Aj, Lam, As, Liem, Jj, Lougheed, Md, Lowe, Dw, Rizvi, Q, van den Berg, L, Zidel, B, Barros Monge MJ, Calvo Gil MA, Castillo Hofer CR, Diaz Amor PV, Lezana Soya, V, Quilodran Silva CN, Bolivar Grimaldos, F, Solarte-Rodriguez, I, Butkovic-Tomljanovic, R, Hegedus-Jungvirth, M, Ivkovic-Jurekovic, I, Simunov-Karuza, G, Buresova, M, Bursova, J, Fratrik, J, Guttlerova, E, Hartman, P, Jirmanova, I, Kalina, P, Kolman, P, Kucera, M, Povysilova, L, Pravda, P, Svabkova, A, Zakova, L, Backer, V, Maltbaek, N, Johnsen, Cr, Aries, Sp, Babyesiza, A, Barth, D, Benedix, A, Berg, P, Bergtholdt, B, Bettig, U, Bindig, Hw, Botzen, U, Brehler, R, Breyer, Go, Bruckhaus-Walter, M, Dapper, T, Eckhard, Jg, Engelhard, R, Feldmeyer, F, Fissan, H, Franz, Kh, Frick, Bs, Funck, J, Gessner, Cm, Ginko, T, Grigat, Ce, Grimm-Sachs, V, Groth, G, Hampf, J, Hanf, G, Havasi-Jost, G, Heinz, Gu, Helm, K, Hoeltz, S, Hofmann, S, Jander, R, Jandl, M, Jasch-Hoppe, B, Jung, T, Junggeburth, Jj, Kardos, P, Knueppel, W, Koch, T, Kolorz, C, Korduan, M, Korth-Wiemann, B, Krezdorn, Hg, Kroker, A, Kruell, M, Kuehne, P, Lenk, U, Liefring, E, Merke, J, Micke, L, Mitlehner, W, Mueller, H, Naudts, If, Neumann, G, Oldenburg, W, Overlack, A, Panzer, F, Reinholz, N, Remppis, R, Riegel, P, Rueckert, P, Schaetzl, Rj, Schauer, U, Hamelmann, E, Schenkenberger, I, Schlegel, V, Scholz, G, Schroers, M, Schwittay, A, Sebert, M, Tyler, K, Soemantri, Pa, Stock, P, Stuchlik, G, Unland, M, von Mallinckrodt, C, Wachter, J, Weber, U, Weberling, F, Wehgartner-Winkler, S, Weimer, J, Wiemer, S, Winkelmann, Ej, Zeisler, Kh, Ziegner, A, Zimny, Hh, Andrasofszky, Z, Bartha, A, Farkas, M, Gömöri, K, Kis, S, Major, K, Mészáros, I, Mezei, M, Rakvacs, M, Szalai, Z, Szántó, J, Szentesi, M, Szolnoki, E, Valyon, E, Zibotics, H, Anwar, J, Arimah, C, Djajalaksana, S, Rai, Ib, Setijadi, Ar, Setyanto, Db, Susanti, F, Syafiuddin, T, Syamsi, Ln, Wijanarko, P, Yunus, F, Bonavia, M, Braga, M, Chetta, Aa, Cerveri, I, Luisetti, M, Crimi, N, Cutrera, R, De Rosa, M, Esposito, S, Foresi, A, Gammeri, E, Iemoli, E, Legnani, Dl, Michetti, G, Pastorello, Ea, Pesci, A, Pistolesi, M, Riva, E, Romano, A, Scichilone, N, Terracciano, L, Tripodi, S, Choi, I, Kim, C, Kim, Js, Kim, Wj, Koh, Yy, Kwon, Ss, Lee, Sh, Lee, S, Lee, Sk, Park, Cs, Cirule, I, Eglite, R, Petrova, I, Poga, M, Smiltena, I, Chomiciene, A, Davoliene, I, Griskeviciene, V, Naudziunas, A, Naudziunas, S, Rudzeviciene, O, Sitkauskiene, B, Urbonas, G, Vaicius, D, Valavicius, A, Valiulis, A, Vebriene, J, bin Abdul Aziz FA, Daud, M, Ismail, Ai, Tengku Saifudin TI, Md Kassim RM, Mohd Fadzli FB, Wan Mohamad WH, Aguilar Dominguez PE, Aguilar-Orozco, Ra, Garza-Salinas, S, Ramirez-Diaz, Sp, Sánchez Llamas, F, Soto-Ramos, M, Velarde-Mora, Hj, Aguirre Sosa, I, Cisneros, Am, Estrella Viladegut RA, Matsuno Fuchigami, A, Adiaz-Baui, Tt, Bernan, Ap, Onia, Af, Sandagon, Mj, S-Naval, S, Yu, Cy, Bartuzi, Z, Bielous-Wilk, A, Błażowski, Ł, Bożek, A, Brzostek, J, Chorostowska-Wynimko, J, Ciekalska, K, Ziora, D, Cieslicki, J, Emeryk, A, Folcik, K, Gałuszka-Bilińska, A, Gawlik, R, Giejlo, M, Harat, R, Hofman, T, Jahnz-Różyk, K, Jedrzejczak, M, Kachel, T, Kamiński, D, Kelm Warchol, A, Konieczny, Z, Kwasniewski, A, Leszczyński, W, Mincewicz, G, Niezgoda, K, Olszewska-Ziąber, A, Onasz-Manitius, M, Pawlukiewicz, M, Piotrowicz, P, Piotrowski, W, Pisarczyk-Bogacka, E, Piskorz, P, Prokop-Staszecka, A, Roslan, A, Słomka, A, Smalera, E, Stelmach, I, Swierczynska-Krepa, M, Szmidt, M, Tarnowska-Matusiak, M, Tłuczykont, B, Tyminska, K, Waszkuc-Golonko, J, Wojciechowska, I, Alexandrescu, Ds, Neamtu, Ml, Todea, D, Alekseeva, E, Aleksandrova, E, Asherova, I, Barbarash, Ol, Bugrova, O, Bukreeva, Eb, Chermenskiy, A, Chizhova, O, Demko, I, Evdokimova, A, Giorgadze, Ml, Grigoryev, S, Irkhina, I, Khurkhurova, Nv, Kondyurina, Eg, Kostin, Vi, Kudelya, L, Laleko, Sl, Lenskaya, L, Levashov, S, Logvinenko, N, Martynov, A, Mizernitski, Y, Nemtsov, B, Novozhenov, Vg, Pavlishchuk, S, Popova, Vv, Reshetko, Ov, Sherenkov, A, Shirinsky, Vs, Shpagina, L, Soloviev, Ki, Tkachev, A, Trofimov, Vi, Vertkin, Al, Vorobeva, E, Idrisova, E, Yakushin, S, Zadionchenko, V, Zhiglinskaya, O, Zykov, K, Dopudja Pantic, V, Nadaskic, R, Nestorovic, B, Skodric Trifunovic, V, Stojanovic, A, Vukcevic, M, Vujic, T, Mitic Milikic, M, Banovcin, P, Horvathova, H, Karako, P Sr, Plutinsky, J, Pribulova, E, Szarazova, M, Zlatos, A, Adams, L, Badat, A, Bassa, A, Breedt, J, Bruning, A, Ellis, Gc, Emanuel, S, Fouche, Lf, Fulat, Ma, Gani, M, Ismail, Ms, Jurgens, Jc, Nell, H, Nieuwoudt, G, Noor, F, Bolliger, Ct, Puterman, As, Siddique, N, Trokis, Js, Vahed, Ya, Van Der Berg BJ, Van der Linden, M, Van Zyl, L, Visser, Ss, Antépara Ercoreca, I, Arnedillo Muñoz, A, Barbe Illa, F, Barreiro López, B, Blanco Aparicio, M, Boada Valmaseda, A, Bosque García, M, Bustamante Ruiz, A, Carretero Anibarro, P, Del Campo Matias, F, Echave-Sustaet, Jm, Espinosa de los Monteros Garde MJ, Garcia Hernandez GM, López Viña, A, Lores Obradors, L, Luengo Planas MT, Monsó Molas, E, Navarro Dourdil, A, Nieto García AJ, Perpina Tordera, M, Picado Valles, C, Rodriguez Alvarez Mdel, M, Saura Vinuesa, A, Serra Batlles, J, Soler Sempere MJ, Toran Montserrat, P, Valdés Cuadrado LG, Villasante Fernandez-Montes, C, Cheng, Sl, Chern, Jh, Chiu, Mh, Chung, Cl, Lai, Rs, Lin, Ck, Liu, Yc, Wang, Cc, Wei, Yf, Amer, L, Berenfus, Vi, Besh, L, Duka, Kd, Fushtey, Im, Garmash, N, Dudnyk, O, Godlevska, O, Vlasenko, Ma, Hospodarskyy, I, Iashyna, L, Kaladze, M, Khvelos, Si, Kostromina, Vp, Krakhmalova, O, Kryuchko, T, Kulynych, Ov, Krasko, Mp, Levchenko, O, Litvinova, T, Panina, Ss, Pasiyeshvili, Lm, Prystupa, Ln, Romaniuk, Li, Sirenko, I, Synenko, Vi, Vynnychenko, Lb, Yatsyshyn, Ri, Zaitsev, I, Zhebel, V, Zubarenko, O, Arthur, Cp, Brown, V, Burhan, H, Chaudhuri, R, Collier, D, Barnes, Nc, Davies, Ej, Ellery, A, Kwok, S, Lenney, W, Nordstrom, M, Pandya, Hc, Parker, Iw, Rajakulasingam, K, Seddon, P, Sharma, R, Thomas, Ec, Wakeling, Ja, Abalos-Galito, M, Abboy, C, Abreu, E, Ackerman, If, Acosta, Ia, Adaoag, Aa, Ahmed, M, Ali, Mi, Allen, Dr, Allen GG Jr, Diogo, Jj, Allison, Dc, Alwine, Lk, Apaliski, Sj, Arastu, Rs, Arora, Cm, Auerbach, D, Azzam, Sj, Badar FL 3rd, Baker, Jw, Barasch, Jp, Barber, Ma, Bardinas-Rodriguez, R, Barreiro, Tj, Baumbach, Rr, Baur, Ce, Baxter, Bs, Beach, Jl, Beasley, Rl, Beavins, Je, Beliveau, Wj, Benbow, Mj, Bennett, Nl, Bennett, Rl, Bernal, H, Bernstein, Di, Blaiss, Ms, Blumenthal, Kw, Boas, Sr, Borders, Jl, Boscia, Ja, Boulware, Wn, Bowling, Bt, Brabec, Ba, Bramlet, Dg, Figueroa, Dp, Brautigam, Df, Brownell, Jm, Bruce, Tr, Call, Rs, Campbell, Ca, Canaan, Ya, Cannon, Df, Carpio, Jm, Cathcart, Ws, Cevallos, Jp, Chauhan, Av, Chuang, Rb, Chevalier, D, Christensen, J, Christensen, Ta, Christina, Mo, Chrzanowski, Rr, Civitarese, Fa, Clark, Jp, Clifford, Dp, Lapidus, Rj, Coggi, Ja, Lenz, Jj, Cohen, Kr, Collins, Bg, Collins, H, Comellas, A, Condit, J, Cordasco EM Jr, Corder, Cn, Covar, Ra, Coverston, Kd, Croce, Sa, Cruz, H, Curtis, Ct, Daftary, Pk, Dalan, D, Dalawari, Sp, Daly, Wc, Davis, Kc, Dawes, Kw, Decotiis, Ba, Deluca, Rf, Desantis, Dm, De Valle OL, Diaz, Jl, Diaz, Jd, Dice, Jp, Elizalde, A, Hosler, Mr, Dixon, C, Dobkin, La, Dobrusin, Rs, Dransfield, Mt, Ebbeling, Wl, Edwards, Jd, Elacion, Jm, Elkayam, D, Ellison, Wt, Elsen, Jr, Engel, Lr, Ensz, Dj, Ericksen, Cl, Ervin, Je, Fang, C, Abrahamian, F, Farrah, Vb, Field, Jd, Fishman, Hj, Florea, R, Nayyar, S, Focil, A, Focauld, F, Franco MA Jr, Frandsen, Br, Ganti, K, Garcia, Fl, Lee, Wm, Garscadden, Ag, Gatti, Ea, Gellady, Am, George, Ar, Gibbon, Gw, Gleason, Gp, Goldberg, P, Goldstein, Mf, Gonzalez, Ge, Gower, Rg, Grande, Ja, Gregory, D, Grubb, Sd, Guthrie, Rp, Haas, Ta, Haft, Ks, Hajal, R, Hammond, Gd, Hansel, Nn, Hansen, Vr, Harris, Af, Hartman, An, Harvey, Rr, Hazan-Steinberg, S, Headley, Dm, Heigerick, Gc, Heller, Bn, Hendrix, El, Herrod, Jn, Hewitt, Mj, Hines, Rl, Hirdt, Ap, Hirschfield, Ja, Hoffman, Ks, Hogan, Ad, Howland, Wc, Hsu, Cc, Hsu, Fj, Hubbard, Wm, Hudson, Jd, Huffman, C, Hussain, M, Ioachimescu, Oc, Ismail, Ym, Jaffrani, Na, Jiang, N, Jones, Sw, Jordan, Rs, Joshi, Ke, Kaashmiri, Mw, Kalafer, M, Kamdar, Ba, Kanuga, Jg, Kao, Nl, Karetzky, M, Katsetos, Jc, Kay, Js, Kimmel, Ma, Kimura, Sh, Kingsley, Jk, Mahmood, Sm, Subich, Dc, Kirstein, Jl, Kleerup, Ec, Klein, Rm, Koh, Dw, Kohli, N, Koura, Fa, Kovacs, Sp, Kratzer, J, Kreit, Ci, Kreutter, Fm, Kubicki, Tm, Labuda, Jm, Latorre, Aj, Lara, Mm, Lechin, Ae, Lee, Jj, Lee, Md, Lentnek, Al, Lesh, Kw, Levins, Pf, Anspach, Rb, Levinsky, Dm, Lillestol, Mj, Lim, H, Livezey, Md, Lloyd-Turney, Cw, Lockey, Rf, Long, Ra, Lynch, Mj, Macgillivray, Bk, Mahadevan, Kp, Makam, Sk, Maloney, Mj, Mapel, D, Margolis, Bd, Margulies, J, Martin, Ef, Martin, Ee, Mascolo, M, Mataria, H, Sunbuli, M, Mathur, Rn, Mattar, Pn, Maynard, Km, Maynard, N, Mccormick, B, Mcelya, M, Mcevoy, Ce, Mckenzie, Wc, Medwedeff, Le, Mehta, Kd, Melamed, Ir, Meli, Jv, Merrick, Bh, Meyers, Pj, Miller, Bt, Minton, Sm, Miranda, Fg, Mohar, De, Montenegro, Ch, Morris, Fa, Morrison, Bs, Moss, Mh, Munoz, F, Naini, Gr, Nakamura, Ct, Naseeruddin, S, Nassim, C, Navazo, Lj, Nissim, Je, Norman, D, Oberoi, Ms, O'Connor, Tm, Offenberger, J, Orr, Rr, Osea, Ea, Paine, Wj, Rasmussen, Nl, Palatnik, M, Pangtay, D, Panuto, Ja, Patel, M, Perera, Ms, Perez, A, Peters PH Jr, Pimentel SM Jr, Pluto, Tm, Pollock, Mt, Posner, Ls, Pritchard, Jc, Pudi, Kk, Puig, Cm, Qaqundah, Py, Radbill, Mk, Rahman, St, Raikhel, M, Raissy, Hh, Ramstad, Ds, Ranasinghe, Es, Rangel, Os, Rapo, Se, Raschal, Sp, Reddy, Dg, Rehman, Sm, Reyes, Sr, Rhodes, Rb, Riffer, E, Rihal, Ps, Riley ED 4th, Rodriguez, Dh, Rogers, Cm, Rohlf, Jl, Romeu, H, Roney, Cw, Ronsick, So, Rosen, Jb, Rowe, Ms, Ruoff, Ge, Ryan, Eh, Saff, Rh, Saini, N, Anand, S, Balakrishnan, K, Samuels, Bs, Samuelson, Rj, Saniuk, Rj, Sargeant, Wo, Saunders, Mk, Saway, W, Scarupa, Md, White, Mv, Schear, Mj, Schwarz, Cm, Scott, Rb, Segall, N, Seibert, Af, Seidmeyer, V, Seidner, Mr, Seifer, Fd, Serje, J, Shah, Ms, Shah, Sb, Shapero, Pa, Shearer, Sd, Sheikh, Sq, Shepherd, Ts, Sher, Er, Sher, Ld, Short, Bh, Silas, Pe, Alvey, Jc, Silverfield, Jc, Simon, Sj, Sitar, S, Skoner, Dp, Smallow, Sa, Smart, Ba, Smith, Ca, Smith, Ke, Smith, Sk, Snyders, Gc, Soong, W, Soufer, J, Spangenthal, S, Stahlman, Je, Steele, Lg, Stegemoller, Rk, Stocks, J, Storms, Ww, Suen, J, Surowitz, Rz, Swauger, Jr, Taber, La, Tan, Ae, Pratt, Se, Tanus, T, Tarpay, Mm, Tarshis, Ga, Tenney, Jw, Tilghman, Kg, Trevino, Me, Troyan, Be, Twiddy, Sk, Updegrove, Jd, Urval, Kr, Uusinarkaus, Kt, Vaela, R, Van Cleeff, M, Varano, S, Vo, Qd, Wainz, Rj, Wald, Ja, Wall, Sj, Wasserman, Rl, Weinstein, Dl, Welker, Ja, Wellmon, B 2nd, Wells, T, Wenocur, Hs, Williams, Dl, Williams, Sl, Win, Ph, Wingo, Td, Wisman PP Jr, Wyszomierski, Da, Yamada, Hm, Yarows, S, Yunger TM Jr, Ziering, Rw., the AUSTRI Investigators, Stempel, D., Raphiou, I., Kral, K., Yeakey, A., Emmett, A., Prazma, C., Buaron, K., and Pascoe, S. Scichilone N tra i collaboratori
- Subjects
Male ,asthma ,serious events ,fluticasone ,salmeterol ,AUSTRI ,Exacerbation ,Intention to Treat Analysi ,INHALED CORTICOSTEROIDS ,Severity of Illness Index ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,immune system diseases ,Ús terapèutic ,Broncodilatadors ,030212 general & internal medicine ,Child ,Fluticasone ,RISK ,ACTING BETA-AGONISTS ,EXACERBATIONS ,METAANALYSIS ,MORTALITY ,SAFETY ,DEATH ,FDA ,Medicine (all) ,Hazard ratio ,General Medicine ,Bronchodilator agents ,Middle Aged ,Fluticasone-Salmeterol Drug Combination ,Bronchodilator Agents ,Intention to Treat Analysis ,Anesthesia ,Female ,Salmeterol ,medicine.drug ,Human ,Adult ,medicine.medical_specialty ,Adolescent ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Fluticasone propionate ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Administration, Inhalation ,medicine ,Humans ,Asma ,Bronchodilator Agent ,Asthma ,Aged ,Proportional Hazards Models ,business.industry ,Therapeutic use ,medicine.disease ,respiratory tract diseases ,030228 respiratory system ,Fluticasone Propionate, Salmeterol Xinafoate Drug Combination ,Proportional Hazards Model ,business - Abstract
BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of lifethreatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone–salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation. RESULTS Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone–salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthmarelated event in the fluticasone–salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P = 0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthmarelated intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone–salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone–salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P
- Published
- 2016
11. Consumer interest in specialty beers in three European markets
- Author
-
Donadini, Gianluca, Fumi, Maria Daria, Kordialik Bogacka, E., Maggi, Luana, Lambri, Milena, Sckokai, Paolo, Fumi, Maria Daria (ORCID:0000-0002-5062-1601), Lambri, Milena (ORCID:0000-0003-4330-2888), Sckokai, Paolo (ORCID:0000-0001-8278-9663), Donadini, Gianluca, Fumi, Maria Daria, Kordialik Bogacka, E., Maggi, Luana, Lambri, Milena, Sckokai, Paolo, Fumi, Maria Daria (ORCID:0000-0002-5062-1601), Lambri, Milena (ORCID:0000-0003-4330-2888), and Sckokai, Paolo (ORCID:0000-0001-8278-9663)
- Abstract
This study explores the quality perception of specialty beers (SBs) in Italy, Spain and Poland. Five-hundred and fifty mainstream beer consumers were enrolled in this study (two-hundred and thirty Italians, one hundred and sixty Poles and Spaniards respectively). The authors adopted a conjoint rating experiment in which the respondents were given forty SB profiles to evaluate. Each profile was described on six attributes (malt type, adjuncts, alternative source of sugars, characterizing ingredients, sensory characteristics, and retail price) varied at different levels and were asked to state his/her preference for each profile on a 9-point scale of interest. The results of this study showed that the ideal SB: (1) for the aggregate Polish panel is brewed from malted wheat, raw wheat, honey, and tropical fruits, is alcoholic and is priced below 2.00 Euros; (2) for the aggregate Italian panel consists of a beer brewed from malted wheat, maize, honey, and vanilla, is blonde and costs a maximum of 2.00 Euros; (3) for the aggregate Spanish panel is brewed from malted wheat, rye or maize, vanilla, is fruity and is priced below 2.00 Euros. The heterogeneity of interest in specialty beers observed in the three countries under test requires for the adaptation of a SB specifically to each culture in which it is sold. In this process of customization, brewers must take into account that gender modulates the effect of culture on consumer interest in SB sensory characteristics and ingredient formulation.
- Published
- 2016
12. Clinical and translational allergy / Research needs in allergy: an EAACI position paper, in collaboration with EFA
- Author
-
Papadopoulos, Nikos G., Agache, I., Bavbek, S., Bilo, B. M., Braido, F., Cardona, V., Custovic, A., Demonchy, J., Demoly, P., Eigenmann, P., Gayraud, J., Grattan, C., Heffler, E., Hellings, P. W., Jutel, M., Knol, E., Lotvall, J., Muraro, A., Poulsen, L. K., Roberts, G., Schmid-Grendelmeier, P., Skevaki, C., Triggiani, M., Vanree, R., Werfel, T., Flood, B., Palkonen, S., Savli, R., Allegri, P., Annesi-Maesano, I., Annunziato, F., Antolin-Amerigo, D., Apfelbacher, C., Blanca, M., Bogacka, E., Bonadonna, P., Bonini, M., Boyman, O., Brockow, K., Burney, P., Buters, J., Butiene, I., Calderon, M., Cardell, L. O., Caubet, J. C., Celenk, S., Cichocka-Jarosz, E., Cingi, C., Couto, M., Dejong, N., Del Giacco, S., Douladiris, N., Fassio, F., Fauquert, J. L., Fernandez, J., Rivas, M. F., Ferrer, M., Flohr, C., Gardner, J., Genuneit, J., Gevaert, P., Groblewska, A., Hamelmann, E., Hoffmann, H. J., Hoffmann-Sommergruber, K., Hovhannisyan, L., Hox, V., Jahnsen, F. L., Kalayci, O., Kalpaklioglu, A. F., Kleine-Tebbe, J., Konstantinou, G., Kurowski, M., Lau, S., Lauener, R., Lauerma, A., Logan, K., Magnan, A., Makowska, J., Makrinioti, H., Mangina, P., Manole, F., Mari, A., Mazon, A., Mills, C., Mingomataj, E., Niggemann, B., Nilsson, G., Ollert, M., O'Mahony, L., O'Neil, S., Pala, G., Papi, A., Passalacqua, G., Perkin, M., Pfaar, O., Pitsios, C., Quirce, S., Raap, U., Raulf-Heimsoth, M., Rhyner, C., Robson-Ansley, P., Alves, R. R., Roje, Z., Rondon, C., Rudzeviciene, O., Rueff, F., Rukhadze, M., Rumi, G., Sackesen, C., Santos, A. F., Santucci, A., Scharf, C., Schmidt-Weber, C., Schnyder, B., Schwarze, J., Senna, G., Sergejeva, S., Seys, S., Siracusa, A., Skypala, I., Sokolowska, M., Spertini, F., Spiewak, R., Sprikkelman, A., Sturm, G., Swoboda, Ines, Terreehorst, I., Toskala, E., Traidl-Hoffmann, C., Venter, C., Vlieg-Boerstra, B., Whitacker, P., Worm, M., Xepapadaki, P., and Akdis, C. A.
- Published
- 2012
- Full Text
- View/download PDF
13. Research needs in allergy: An EAACI position paper, in collaboration with EFA
- Author
-
Papadopoulos, N.G. Agache, I. Bavbek, S. Bilo, B.M. Braido, F. Cardona, V. Custovic, A. DeMonchy, J. Demoly, P. Eigenmann, P. Gayraud, J. Grattan, C. Heffler, E. Hellings, P.W. Jutel, M. Knol, E. Lötvall, J. Muraro, A. Poulsen, L.K. Roberts, G. Schmid-Grendelmeier, P. Skevaki, C. Triggiani, M. VanRee, R. Werfel, T. Flood, B. Palkonen, S. Savli, R. Allegri, P. Annesi-Maesano, I. Annunziato, F. Antolin-Amerigo, D. Apfelbacher, C. Blanca, M. Bogacka, E. Bonadonna, P. Bonini, M. Boyman, O. Brockow, K. Burney, P. Buters, J. Butiene, I. Calderon, M. Cardell, L.O. Caubet, J.-C. Celenk, S. Cichocka-Jarosz, E. Cingi, C. Couto, M. DeJong, N. Del Giacco, S. Douladiris, N. Fassio, F. Fauquert, J.-L. Fernandez, J. Rivas, M.F. Ferrer, M. Flohr, C. Gardner, J. Genuneit, J. Gevaert, P. Groblewska, A. Hamelmann, E. Hoffmann, H.J. Hoffmann-Sommergruber, K. Hovhannisyan, L. Hox, V. Jahnsen, F.L. Kalayci, Ö. Kalpaklioglu, A.F. Kleine-Tebbe, J. Konstantinou, G. Kurowski, M. Lau, S. Lauener, R. Lauerma, A. Logan, K. Magnan, A. Makowska, J. Makrinioti, H. Mangina, P. Manole, F. Mari, A. Mazon, A. Mills, C. Mingomataj, E.Ç. Niggemann, B. Nilsson, G. Ollert, M. O'Mahony, L. O'Neil, S. Pala, G. Papi, A. Passalacqua, G. Perkin, M. Pfaar, O. Pitsios, C. Quirce, S. Raap, U. Raulf-Heimsoth, M. Rhyner, C. Robson-Ansley, P. Alves, R.R. Roje, Z. Rondon, C. Rudzeviciene, O. Ruëff, F. Rukhadze, M. Rumi, G. Sackesen, C. Santos, A.F. Santucci, A. Scharf, C. Schmidt-Weber, C. Schnyder, B. Schwarze, J. Senna, G. Sergejeva, S. Seys, S. Siracusa, A. Skypala, I. Sokolowska, M. Spertini, F. Spiewak, R. Sprikkelman, A. Sturm, G. Swoboda, I. Terreehorst, I. Toskala, E. Traidl-Hoffmann, C. Venter, C. Vlieg-Boerstra, B. Whitacker, P. Worm, M. Xepapadaki, P. Akdis, C.A.
- Abstract
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century. The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels. Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein. © 2012 Papadopoulos et al.
- Published
- 2012
14. Stimulation of gluten-free sourdough fermentation
- Author
-
Diowksz, A., primary and Kordialik-Bogacka, E., additional
- Published
- 2014
- Full Text
- View/download PDF
15. Research needs in allergy: An EAACI position paper, in collaboration with EFA
- Author
-
Papadopoulos, N., Agache, I., Bavbek, S. (Sevim), Bilo, B.M. (Beatrice M.), Braido, F. (Fulvio), Cardona, D. (Doris), Custovic, A. (Adnan), DeMonchy, J. (Jan), Demoly, P., Eigenmann, P.A. (Philippe), Gayraud, J. (J.), Grattan, C., Heffler, E. (E.), Hellings, P.W. (Peter), Jutel, M. (M.), Knol, E.F. (Edward Frank), Lötvall, J. (Jan), Murarol, A. (Antonella), Poulsen, L.K., Roberts, G., Schmid-Grendelmeier, P. (Peter), Skevaki, C. (Chrysanthi), Triggiani, M. (M.), VanRee, R. (Ronald), Werfel, T., Flood, B. (Breda), Palkonen, S., Savli, R. (Roberta), Allegri, P. (Pia), Annesi-Maesano, I. (Isabella), Annunziato, F. (Francesco), Antolin-Amerigo, D. (Dario), Apfelbacher, M. (Manuela), Blanca, M. (Miguel), Bogacka, E. (Ewa), Bonadonna, P. (Patrizia), Bonini, M. (Matteo), Boyman, O. (Onur), Brockow, K. (Knut), Burney, P. (Peter), Buters, J. (Jeroen), Butiene, I. (Indre), Calderon, M. (Moises), Cardell, L.O., Caubet, J.-C. (Jean-Christoph), Celenk, S. (Sevcan), Cichocka-Jarosz, E., Cingi, C. (Cemal), Couto, M. (Mariana), DeJong, N. (Nicolette), Del Giacco, S. (Stefano), Douladiris, N. (Nikolaos), Fassio, F. (Filippo), Fauquert, J.-L. (Jean-Luc), Fernandez, J. (Javier), Rivas, M.F. (Montserrat Fernandez), Ferrer, M. (Marta), Flohr, C. (Carsten), Gardner, J. (James), Genuneit, J. (Jon), Gevaert, P. (P.), Groblewska, A. (Anna), Hamelmann, E. (Eckard), Hoffmann, H.J. (Hans Jürgen), Hoffmann-Sommergruber, K. (K.), Hovhannisyan, L. (Lilit), Hox, V. (Valérie), Jahnsen, F.L. (Frode L.), Kalayci, O. (Omer), Kalpaklioglu, A.F. (Ayse Füsun), Kleine-Tebbe, J. (Jörg), Konstantinou, G. (George), Kurowski, M. (Marcin), Lau, S. (Susanne), Lauener, R. (Roger), Lauerma, A. (Antti), Logan, K. (K.), Magnan, A. (Antoine), Makowska, J. (Joanna), Makrinioti, H. (Heidi), Mangina, P. (Paraskevi), Manole, F. (Felicia), Mari, A. (A.), Mazón, A., Mills, C. (Clare), Mingomataj, E.Ç. (Ervin Ç), Niggemann, B., Nilsson, G. (Gunnar), Ollert, M. (Markus), O'Mahony, L. (Liam), O'Neil, S. (Serena), Pala, G. (Gianni), Papi, A. (Alberto), Passalacqua, G. (Giovanni), Perkin, M. (Michael), Pfaar, O. (Oliver), Pitsios, C., Quirce, S. (S.), Raap, U., Raulf-Heimsoth, M., Rhyner, C. (Claudio), Robson-Ansley, P. (Paula), Alves, R.R. (Rodrigo Rodrigues), Roje, Z. (Zeljka), Rondon, C. (Carmen), Rudzeviciene, O. (Odilija), Rueff, F. (Franziska), Rukhadze, M. (Maia), Rumi, G. (Gabriele), Sackesen, C. (Cansin), Santos, A.F. (Alexandra F.), Santucci, A. (Annalisa), Scharf, C. (Christian), Schmidt-Weber, C.B., Schnyder, B. (Benno), Schwarze, J. (Jürgen), Senna, G.E. (Gianenrico), Sergejeva, S. (Svetlana), Seys, S. (Sven), Siracusa, A. (Andrea), Skypala, I. (I.), Sokolowska, M. (Milena), Spertini, F. (Francois), Spiewak, R. (Radoslaw), Sprikkelman, A.B. (Aline), Sturm, G.J., Swoboda, I., Terreehorst, I., Toskala, E., Traidl-Hoffmann, C. (Claudia), Venter, C. (C.), Vlieg-Boerstra, B.J., Whitacker, P. (Paul), Worm, M. (M.), Xepapadaki, P. (Paraskevi), Akdis, C.A., Papadopoulos, N., Agache, I., Bavbek, S. (Sevim), Bilo, B.M. (Beatrice M.), Braido, F. (Fulvio), Cardona, D. (Doris), Custovic, A. (Adnan), DeMonchy, J. (Jan), Demoly, P., Eigenmann, P.A. (Philippe), Gayraud, J. (J.), Grattan, C., Heffler, E. (E.), Hellings, P.W. (Peter), Jutel, M. (M.), Knol, E.F. (Edward Frank), Lötvall, J. (Jan), Murarol, A. (Antonella), Poulsen, L.K., Roberts, G., Schmid-Grendelmeier, P. (Peter), Skevaki, C. (Chrysanthi), Triggiani, M. (M.), VanRee, R. (Ronald), Werfel, T., Flood, B. (Breda), Palkonen, S., Savli, R. (Roberta), Allegri, P. (Pia), Annesi-Maesano, I. (Isabella), Annunziato, F. (Francesco), Antolin-Amerigo, D. (Dario), Apfelbacher, M. (Manuela), Blanca, M. (Miguel), Bogacka, E. (Ewa), Bonadonna, P. (Patrizia), Bonini, M. (Matteo), Boyman, O. (Onur), Brockow, K. (Knut), Burney, P. (Peter), Buters, J. (Jeroen), Butiene, I. (Indre), Calderon, M. (Moises), Cardell, L.O., Caubet, J.-C. (Jean-Christoph), Celenk, S. (Sevcan), Cichocka-Jarosz, E., Cingi, C. (Cemal), Couto, M. (Mariana), DeJong, N. (Nicolette), Del Giacco, S. (Stefano), Douladiris, N. (Nikolaos), Fassio, F. (Filippo), Fauquert, J.-L. (Jean-Luc), Fernandez, J. (Javier), Rivas, M.F. (Montserrat Fernandez), Ferrer, M. (Marta), Flohr, C. (Carsten), Gardner, J. (James), Genuneit, J. (Jon), Gevaert, P. (P.), Groblewska, A. (Anna), Hamelmann, E. (Eckard), Hoffmann, H.J. (Hans Jürgen), Hoffmann-Sommergruber, K. (K.), Hovhannisyan, L. (Lilit), Hox, V. (Valérie), Jahnsen, F.L. (Frode L.), Kalayci, O. (Omer), Kalpaklioglu, A.F. (Ayse Füsun), Kleine-Tebbe, J. (Jörg), Konstantinou, G. (George), Kurowski, M. (Marcin), Lau, S. (Susanne), Lauener, R. (Roger), Lauerma, A. (Antti), Logan, K. (K.), Magnan, A. (Antoine), Makowska, J. (Joanna), Makrinioti, H. (Heidi), Mangina, P. (Paraskevi), Manole, F. (Felicia), Mari, A. (A.), Mazón, A., Mills, C. (Clare), Mingomataj, E.Ç. (Ervin Ç), Niggemann, B., Nilsson, G. (Gunnar), Ollert, M. (Markus), O'Mahony, L. (Liam), O'Neil, S. (Serena), Pala, G. (Gianni), Papi, A. (Alberto), Passalacqua, G. (Giovanni), Perkin, M. (Michael), Pfaar, O. (Oliver), Pitsios, C., Quirce, S. (S.), Raap, U., Raulf-Heimsoth, M., Rhyner, C. (Claudio), Robson-Ansley, P. (Paula), Alves, R.R. (Rodrigo Rodrigues), Roje, Z. (Zeljka), Rondon, C. (Carmen), Rudzeviciene, O. (Odilija), Rueff, F. (Franziska), Rukhadze, M. (Maia), Rumi, G. (Gabriele), Sackesen, C. (Cansin), Santos, A.F. (Alexandra F.), Santucci, A. (Annalisa), Scharf, C. (Christian), Schmidt-Weber, C.B., Schnyder, B. (Benno), Schwarze, J. (Jürgen), Senna, G.E. (Gianenrico), Sergejeva, S. (Svetlana), Seys, S. (Sven), Siracusa, A. (Andrea), Skypala, I. (I.), Sokolowska, M. (Milena), Spertini, F. (Francois), Spiewak, R. (Radoslaw), Sprikkelman, A.B. (Aline), Sturm, G.J., Swoboda, I., Terreehorst, I., Toskala, E., Traidl-Hoffmann, C. (Claudia), Venter, C. (C.), Vlieg-Boerstra, B.J., Whitacker, P. (Paul), Worm, M. (M.), Xepapadaki, P. (Paraskevi), and Akdis, C.A.
- Abstract
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century. The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels. Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and tre
- Published
- 2012
- Full Text
- View/download PDF
16. Regeneration of biomass used in the biosorption of cadmium
- Author
-
Kordialik-Bogacka, E., primary, Smolińska, B., additional, Cedzyńska, K., additional, and Ambroziak, W., additional
- Published
- 2009
- Full Text
- View/download PDF
17. The Effectiveness of Allergen Immunotherapy Depending on the Regimen on Rhinoconjunctivitis and Asthma Symptoms in Allergy to Grass Pollen.
- Author
-
Bochenska-Marciniak, M, primary, Tworek, D, additional, Kupczyk, M, additional, Bogacka, E, additional, Kuprys-Lipinska, I, additional, and Kuna, P, additional
- Published
- 2009
- Full Text
- View/download PDF
18. Management of allergic rhinitis
- Author
-
Bogacka, E., primary
- Published
- 1999
- Full Text
- View/download PDF
19. Relation of filaggrin null mutations with atopy in Croatia
- Author
-
Sabolic Pipinic, Ivana, Varnai, Veda Marija, Turk, Rajka, Breljak, Davorka, Kezic, Sanja, Macan, Jelena, Bavbek, S., Bilo, B., and Bogacka, E. et al.
- Subjects
body regions ,eczema/dermatitis ,filaggrin ,gene polymorphism ,skin prick testing - Abstract
Background: Null mutations in the gene encoding filaggrin (FLG), which result in the loss of filaggrin production and hence disrupt the epidermal barrier function, have been strongly associated with atopic dermatitis and present a predisposing factor in the development of the atopic march. The frequencies of the most common null mutations among the Caucasian population in Western Europe and North America were analyzed in young adult Croatian population, and their relation to skin and respiratory atopic diseases was assessed. Method: FLG null mutations R501X, 2282del4, R2447X and S3247X were genotyped in 423 students (305 females and 118 males, median age 19 years) with defined atopic phenotype (atopic dermatitis, rhinitis and asthma) by means of recorded atopic skin and respiratory symptoms with modified ISAAC questionnaire and positive skin prick testing (SPT) to one or more common inhalatory allergens. Result: We found 11 FLG null mutations carriers, 1/423 (0.2%) heterozygous for R501X and 10/423 (2, 4%) heterozygous for 2282del4. There were no carriers of R2447X and S3247X mutations. In total sample (N=423), atopic dermatitis was present in 12%, rhinitis in 17% and asthma in 7% of subjects. FLG null mutations were not related to any analyzed atopic phenotype. Among 11 FLG null mutations carriers only 3 (27.3%) had atopic dermatitis, but 9 had eczema/dermatitis symptoms regardless of positive SPT. Multiple logistic regression analysis, controlled for gender, family history of skin allergies and positive SPT, confirmed FLG null mutations as an independent risk factor for presence of eczema/dermatitis symptoms (OR 22, 95%CI 4.4-109.4 ; P
- Published
- 2011
20. Antibacterial efficacy of berry juices against Bacillus cereus relative to their phytochemical composition and antioxidant properties.
- Author
-
Królak K, Ścieszka S, Kordialik-Bogacka E, Oracz J, Ditrych M, Szczygieł T, Dybka-Stępień K, Otlewska A, and Żyżelewicz D
- Subjects
- Fruit chemistry, Plant Extracts pharmacology, Plant Extracts chemistry, Ribes chemistry, Photinia chemistry, Sambucus nigra chemistry, Anthocyanins pharmacology, Anthocyanins analysis, Anthocyanins chemistry, Vaccinium macrocarpon chemistry, Microbial Sensitivity Tests, Bacillus cereus drug effects, Antioxidants pharmacology, Antioxidants chemistry, Fruit and Vegetable Juices analysis, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Phytochemicals chemistry, Phytochemicals pharmacology, Phytochemicals analysis
- Abstract
Ensuring the safety and stability of minimally processed foods using natural preservatives is of great scientific and commercial interest in modern biotechnology. Berry juice supplementation is increasingly recognized within this field. This study investigated the effectiveness of juices from four berry species Aronia melanocarpa, Ribes nigrum, Vaccinium macrocarpon, and Sambucus nigra, against the food pathogen Bacillus cereus. Overall, the antibacterial potency of juice supplements (up to 10% v/v in tryptic soy broth) followed the order of chokeberry > blackcurrant > cranberry > elderberry, with the latter showing no inhibitory effects. Notably, chokeberry and elderberry juices presented lower acidity and significantly greater phenolic contents (p < 0.05) than blackcurrant and cranberry juices did, suggesting that B. cereus susceptibility is not strictly dependent upon low extracellular pH or elevated anthocyanin levels. Instead, it is inferred to correlate with pro-oxidative effects induced directly at the intracellular level. Accordingly, this paper discusses the antioxidative, acidic, and lipophilic attributes of juices and their constituent fractions, including anthocyanins, to elucidate their biopreservative potential. The results of this study increase our understanding of the antibacterial susceptibility of B. cereus., Competing Interests: Declarations Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Biopreservation of beer: Potential and constraints.
- Author
-
Kordialik-Bogacka E
- Subjects
- Animals, Anti-Bacterial Agents, Food Microbiology, Anti-Infective Agents pharmacology, Beer microbiology
- Abstract
The biopreservation of beer, using only antimicrobial agents of natural origin to ensure microbiological stability, is of great scientific and commercial interest. This review article highlights progress in the biological preservation of beer. It describes the antimicrobial properties of beer components and microbiological spoilage risks. It discusses novel biological methods for enhancing beer stability, using natural antimicrobials from microorganisms, plants, and animals to preserve beer, including legal restrictions. The future of beer preservation will involve the skilled knowledge-based exploitation of naturally occurring components in beer, supplementation with generally regarded as safe antimicrobial additives, and mild physical treatments., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
22. The Profiles of Low Molecular Nitrogen Compounds and Fatty Acids in Wort and Beer Obtained with the Addition of Quinoa ( Chenopodium quinoa Willd.), Amaranth ( Amaranthus cruentus L.) or Maltose Syrup.
- Author
-
Bogdan P, Kordialik-Bogacka E, Czyżowska A, Oracz J, and Żyżelewicz D
- Abstract
Replacement of a part of malt with unmalted materials is a common practice in beer production. These materials may differ in chemical composition than barley malt, which in turn can contribute to changes in the final composition of the wort. Consequently, it may affect yeast metabolism and final parameters of the obtained products. In this research, two unmalted pseudocereals were used: quinoa (Chenopodium quinoa Willd.) and amaranth ( Amaranthus cruentus L.). Maltose syrup was tested as a reference material due to its commercial usage as a substitute of malt in production of worts. Replacement of a part of the malt with quinoa or amaranth favorably influenced the profiles of amino and fatty acids. Due to the fact that the type and concentration of individual amino acids and fatty acids in the fermented wort significantly affect the flavor compounds synthesized by yeast, differences in the profiles of esters and higher alcohol have been noted in beers produced with pseudocereals.
- Published
- 2020
- Full Text
- View/download PDF
23. Investigating patterns of millennials' interest in gluten-free beer in Poland: A question of beer price and alcohol content.
- Author
-
Donadini G, Bertuzzi T, Kordialik-Bogacka E, Cywińska D, Rossi F, Spigno G, and Porretta S
- Subjects
- Adult, Alcohols economics, Beer analysis, Color, Commerce, Consumer Behavior economics, Enzyme-Linked Immunosorbent Assay methods, Female, Glutens economics, Humans, Male, Poland, Young Adult, Alcohols analysis, Beer economics, Glutens analysis
- Abstract
The quality perception of gluten-free beer was explored using conjoint analysis with a panel of Polish millennials (n = 200; aged 20 to 35), who were given 64 gluten-free beer concepts to evaluate and score on a 9-point scale of interest (1 = not interested at all; 9 = extremely interested). The constituent factors of the beer concepts were alcohol content, color, type of malt, price, drinking location and occasion, bottle size, label claims, type of farming, type of brewer, and bottle closure. Consumers judged price (38.4%) and alcohol (28.8%) five times more important than the other factors. Bottle size (5.3%), claims (4.8%), type of brewer (4.8%), malt type (4.6%), bottle closure (4.0%), beer color (3.6%), drinking location (2.3%), drinking occasion (2.0%), and type of farming (1.3%) were considered of little importance. The interest of Polish Millennials in gluten-free beer resulted moderate and not linked to medical needs. Males were more interested in gluten-free beers and gave more importance to alcohol content and less importance to price, compared to females. However, for both genders, interest and price were inversely correlated, while interest and alcohol content were directly correlated. PRACTICAL APPLICATION: The identification of the product factors that are preferred by consumers is paramount to translate consumers' needs and expectations into a beer designed to produce the best possible product in a relatively short period. Including information directly obtained from consumers before final design decisions are taken on the final beer output, helps ensuring development directions are on target and constitutes a cost-competitive approach to product development., (© 2019 Institute of Food Technologists®.)
- Published
- 2020
- Full Text
- View/download PDF
24. Suitability of unmalted quinoa for beer production.
- Author
-
Kordialik-Bogacka E, Bogdan P, Pielech-Przybylska K, and Michałowska D
- Subjects
- Fermentation, Humans, Seeds chemistry, Taste, Beer analysis, Chenopodium quinoa chemistry, Food Additives chemistry, Food Handling methods, Hordeum chemistry
- Abstract
Background: This study provides the first detailed investigation into the effect of partially substituting barley malt with quinoa (Chenopodium quinoa Willd.) on the characteristics of wort and beer. Quinoa seeds and flakes were compared in terms of their suitability for brewing. The benefits of applying a commercial enzyme mixture during beer production with quinoa were also investigated., Results: These findings show that quinoa is a good starchy raw material for brewing. Even without exogenous enzymes, it is possible to substitute barley malt with up to 30% quinoa. The form in which quinoa is used has a negligible influence on the quality of the wort and beer. The foam stability of beer made with quinoa was better than that of all-malt beer, despite there being a lower level of soluble nitrogen in quinoa beer in comparison with all-malt beer and more than twice the amount of fat in quinoa in comparison to barley malt., Conclusion: The addition of unmalted quinoa does not give unpleasant characteristics to the beer and was even found to have a positive effect on its overall sensory quality. This offers brewers an opportunity to develop good beers with new sensory characteristics. © 2018 Society of Chemical Industry., (© 2018 Society of Chemical Industry.)
- Published
- 2018
- Full Text
- View/download PDF
25. Metal uptake capacity of modified Saccharomyces pastorianus biomass from different types of solution.
- Author
-
Kordialik-Bogacka E and Diowksz A
- Subjects
- Biodegradation, Environmental, Biomass, Cadmium chemistry, Copper metabolism, Metals analysis, Water Pollutants, Chemical analysis, Metals metabolism, Saccharomyces metabolism, Water Pollutants, Chemical metabolism
- Abstract
In this paper, we investigate the effect of different biomass pretreatments on metal ion uptake by various biosorbents. Heat-treated as well as caustic-treated and ground biomass of Saccharomyces pastorianus was used to remove copper, lead and cadmium from various solutions. Untreated yeast was used as the control sample. The effect of yeast modification on sorption capacity depended on the different types of heavy metal ions and whether they were in single- or multi-component solutions. The highest uptake of copper and lead from a single-metal solution was obtained from heat-treated cells. Ground biomass was the most efficient at cadmium removal. However, the sorption capacity of the modified biomass did not improve when metal ions were removed from multi-component solutions. Indeed, the results in this paper show that optimizing metal removal from single-cation solutions can lead to decreased sorption capacity in multi-component solutions. Therefore, while adjusting the procedure of biomass modification, not only the nature of the metal ion being sorbed but also the chemical composition of the metal ion solution should be taken into account.
- Published
- 2014
- Full Text
- View/download PDF
26. Chronic disease in the elderly: a vital rationale for the revival of internal medicine.
- Author
-
Panaszek B, Machaj Z, Bogacka E, and Lindner K
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Forecasting, Humans, Prevalence, Chronic Disease epidemiology, Chronic Disease therapy, Health Services for the Aged trends, Internal Medicine trends
- Abstract
The phenomenon of population aging has led to a significant rise in the chronic disease rate compared to other human pathologies. Elderly people are usually affected by > or =2 chronic diseases concomitantly, mainly cardiovascular, pulmonary, and central nervous system diseases, metabolic disturbances and cancer. Chronic comorbidities in elderly patients may worsen their clinical status, making both the diagnosis and treatment more difficult. Meanwhile, contemporary medicine is focused on its subspecialties, thus turning away from the tradition of great, academic-based, general internal medicine. Clinical practice is dominated by a specific approach to a single disease rather than a patient with comorbidities. Therefore, an accurate diagnosis, ensuring effective treatment in the case of a complex and ambiguous clinical picture, is based on an attempt to combine multiple expert consultations rather than make a holistic evaluation, so characteristic of traditional internal medicine. For that reason, pathophysiology and clinical picture of a chronic disease in the elderly requires the revival of internal medicine, which is also essential to the development of geriatrics.
- Published
- 2009
27. [Polish agreement in ocular allergy diagnostics and treatment].
- Author
-
Bogacka E, Górski P, Groblewska A, Misiuk-Hojło M, Jedrzejczak-Czechowicz M, Pałczynski C, Zaleska-Zmijewska A, Kune P, and Szaflika J
- Subjects
- Anti-Allergic Agents therapeutic use, Asthma complications, Conjunctivitis, Allergic classification, Conjunctivitis, Allergic etiology, Dermatitis, Atopic complications, Disease Progression, Humans, Hypersensitivity complications, Keratoconjunctivitis diagnosis, Keratoconjunctivitis therapy, Occupational Diseases complications, Ophthalmic Solutions therapeutic use, Poland, Societies, Medical standards, Conjunctivitis, Allergic diagnosis, Conjunctivitis, Allergic therapy, Hygiene standards, Hypersensitivity therapy, Practice Guidelines as Topic, Primary Prevention standards
- Published
- 2008
28. [Cyclohaler's acceptance by asthma and COPD patients].
- Author
-
Panaszek B, Emeryk A, Nittner-Marszalska M, Bogacka E, Gietkiewicz K, Machaj Z, Czerwińska-Pawluk I, and Bednarek A
- Subjects
- Adult, Anti-Asthmatic Agents administration & dosage, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Compliance, Patient Satisfaction, Surveys and Questionnaires, Asthma drug therapy, Nebulizers and Vaporizers, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
Introduction: The patients' acceptance of the treatment scheme and their readiness to stick to the prescribed dosing is considered to be the most important condition on which successful treatment of asthma and COPD depends. With regard to this assumption, a study was designed whose aim was to find out how patients assess a particular powder inhaler, cyclohaler and to what degree they approve of its physical and technical features., Material and Methods: The study consisted in completing an anonymous questionnaire. The study group was recruited from asthmatic and COPD patients treated in outpatient units in Wroclaw and Lublin, Poland. 230 persons passed the recruitment stage, 220 completed the study., Results: 96.4 and 94.5% of the patients ranked small size and low weight of the inhaler, respectively, as its most positive features, ranking the features higher than the device's colour (respectively p = 0.003 and p = 0.02). Other features, like dust protection and comfortable mouthpiece won almost equally high evaluation (respectively 97.3 and 98.2%). Most patients assessed these features as more important than discretion and easy handling and transportation (respectively p = 0.015 and p = 0.028). A high percentage of the study group praised the inhaler's technological efficacy. 94-96% at the least gave positive opinions about such features as: clear instruction, certainty of a dose's intake, the possibility of checking the amount of inhaled doses., Conclusion: The inhaler that was the object of the study enjoyed a high degree of acceptance mostly due to its features facilitating easy and efficient inhalation.
- Published
- 2007
29. [The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
- Author
-
Kupczyk M, Bogacka E, Bocheńska-Marciniak M, Sterchaluk-Grzyb E, Tworek D, and Kuna P
- Subjects
- Administration, Oral, Adult, Albuterol therapeutic use, Asthma complications, Asthma diagnosis, Bronchodilator Agents therapeutic use, Drug Administration Schedule, Female, Humans, Loratadine administration & dosage, Male, Nasal Provocation Tests, Poland, Rhinitis, Allergic, Seasonal complications, Rhinitis, Allergic, Seasonal diagnosis, Severity of Illness Index, Statistics, Nonparametric, Surveys and Questionnaires, Treatment Outcome, Anti-Allergic Agents administration & dosage, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Histamine H1 Antagonists, Non-Sedating administration & dosage, Loratadine analogs & derivatives, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Seasonal allergic rhinitis (SAR) and intermittent asthma are frequently comorbid and share some pathophysiological, clinical and epidemiological bases which has been confirmed by ARIA (Allergic Rhinitis and its Impact on Asthma) WHO position paper. Therapeutical consequences of H1 receptor antagonists treatment in patients with both SAR and asthma are not clear. The aim of this study was to evaluate the effect of desloratadine (5 mg daily) on rescue medication use, symptoms of SAR and asthma. One hundred and ninteen patients (59 men), mean age 29.64 +/- 8.34 years, suffering from SAR and asthma were recruited. After 14 days of screening during the pollen season desloratadine in an open manner was introduced. During the treatment phase mean beta2 agonist weekly demand decreased from 11.73 +/- 8.91 (screening) to 4.89 +/- 7.09 (p < 0.001, Wilcoxon test). Mean symptoms score decreased from 13.37 +/- 5.93 to 5.19 +/- 4.7 and from 5.69 +/- 3.83 to 2.09 +/- 2.45 for SAR and asthma respectively (p < 0.001). Eight mild adverse events were reported with the most frequent-sleepiness (6.9% of study group). Desloratadine in the dosis of 5 mg daily confirmed its efficacy and safety in the treatment of patients with SAR and asthma. Decrease of beta2-agonist use and reduction of diseases symptoms was documented in patients with seasonal allergic rhinitis and asthma.
- Published
- 2005
30. [Epidemiology of allergic eye diseases].
- Author
-
Bogacka E
- Subjects
- Humans, Immunoglobulin E immunology, Conjunctivitis, Allergic epidemiology, Conjunctivitis, Allergic immunology
- Abstract
Epidemiology of allergic eye diseases has not been sufficiently studied so far. The first statistical studies regarded the coexistence of allergic conjunctivitis together with allergic rhinitis, as rhinoconjunctivitis. Only in the last 10 years eye allergy has been regarded as a separate epidemiological and clinical problem. According to Bonini, seasonal allergic conjunctivitis (SAC) accompanies pollinosis in 95.2%. Buckley's studies revealed symptoms of SAC in 21% of British population and Berdy reported a similar result in 20% of Americans. Weeke estimates that depending on geographical region and age of examined patients, allergic eye diseases occur in 5 to 22% of the population. Among them SAC and perennial allertgic conjunctivitis (PAC) account for up to 50%. A recent Italian study demonstrated an increase of the incidence of allergic eye diseases, which were found in 38% of the studied population, most frequently in young males. Eye allergy presented most frequently as rhinoconjunctivitis (SAC and PAC) (63.7%), and then as atopic keratoconjunctivitis (AKC) (21%) and vernal keratoconjunctivitis (VKC) (15.5%). It seems that the incidence of allergic eye diseases demonstrates a rising tendency, similarly as it has been found in recent years in the case of bronchial asthma, rhinitis or atopic dermatitis.
- Published
- 2003
31. [Allergy to fungal antigens].
- Author
-
Bogacka E and Jahnz-Rózyk K
- Subjects
- Alternaria immunology, Ascomycota immunology, Aspergillosis, Allergic Bronchopulmonary immunology, Basidiomycota immunology, Cladosporium immunology, Dermatitis, Allergic Contact immunology, Humans, Antigens, Fungal immunology, Hypersensitivity immunology, Immunoglobulin E immunology
- Abstract
Fungi from human environment or growing in human body may cause allergic reactions. The most common allergens are microfungi (moulds) belonging to imperfect fungi: Alternaria, Cladosporium and sack-like forms: Aspergillus, Penicillium and yeasts. Fungal antigens may stimulate production of specific IgE in atopic individuals what, as a rule, worsens the clinical course of atopic diseases: allergic sinusitis, bronchial asthma or atopic dermatitis. Fungi may also cause IgE-independent allergic reactions: by production of IgE, immunological complexes and by stimulating cell hypersensitivity. Whether allergic bronchopulmonary aspergillosis (ABPA), allergic fungal sinusitis (AFS) or allergic dermatitis appears, depends on the immunological state of human organism and exposure to fungal antigens.
- Published
- 2003
32. [Treatment of allergy to mould spores].
- Author
-
Jahnz-Rózyk K and Bogacka E
- Subjects
- Humans, Immunoglobulin E immunology, Steroids, Anti-Inflammatory Agents therapeutic use, Histamine H1 Antagonists therapeutic use, Histamine H2 Antagonists therapeutic use, Hypersensitivity drug therapy, Hypersensitivity immunology, Spores, Fungal immunology
- Abstract
The treatment of mould allergy is discussed in this article. The specific immunotherapy should be especially considered in this group of patients.
- Published
- 2003
33. [Allergy to mould allergens as a risk factor for bronchial asthma in patients suffering from allergic rhinitis].
- Author
-
Bogacka E, Nittner-Marszalska M, Fal AM, Kuzniar J, Nikiel E, and Małolepszy J
- Subjects
- Adolescent, Adult, Child, Female, Humans, Male, Middle Aged, Risk Factors, Asthma etiology, Hypersensitivity complications, Hypersensitivity immunology, Hypersensitivity microbiology, Rhinitis, Allergic, Perennial complications, Spores, Fungal immunology
- Abstract
Unlabelled: The ARIA study demonstrates the correlation between bronchial asthma (BA) and perennial rhinitis (PR) with mite or animal fur allergies. There are no reports concerning correlation between BA and PR with mould allergy. The authors of this study estimated the prevalence of BA in patients with PR, allergic to moulds in comparison with patients allergic to other aeroallergens. 460 patients suffering from PR were investigated: 102 were allergic to moulds (mono- or multisensitization type) and 358 were allergic to other allergens. The prevalence of BA in mould-sensitive and insensitive patients was 70.6% and 43.6%, respectively; it was significantly higher in the mould-sensitive group (p = 0.004) regardless of the type of mould hypersensitivity (mono- or multisensitization). The higher prevalence of BA in mould-sensitive patients was found to be valid only for adults. The adult PR patients with diagnosed BA were most frequently allergic to Alternaria (47.1%) and Cladosporium (30.8%)., In Conclusion: mould allergy may be a risk factor for BA development.
- Published
- 2003
34. [Health threats for children in the modern building trade].
- Author
-
Bogacka E
- Subjects
- Child, Construction Materials adverse effects, Environmental Exposure adverse effects, Environmental Exposure analysis, Environmental Monitoring, Humans, Hypersensitivity etiology, Neoplasms etiology, Neurotoxins adverse effects, Neurotoxins analysis, Respiratory Hypersensitivity etiology, Air Pollution, Indoor adverse effects, Sick Building Syndrome etiology
- Abstract
Changes in building industry during last 30 years in search of economic technologies and building materials ended in creating airtight and energy-saving constructions with reduced ventilation. As a result, diminish exchange between internal and external air, leads to cumulation of various chemicals and organic substances in our houses. Concentrated oxidation products (CO2, CO, NO2, nicotine smoke), vaporizing substances (formaldehyde, NH3, aromatic hydrocarbons) might irritate mucouses, promote or intense respiratory tract infections, allergic diseases or bronchial asthma. Higher risk of atopic diseases and bronchial asthma also arises from proliferation of fungus, bacteria and mites in modern interiors, which are quite convenient for it. Buildings with microclimate, which is dangerous for human health, are termed "sick buildings". Diseases that develop under their influence are called BRI (building related illnesses). Children are most exposed on them, especially under municipal conditions, because they spend majority of their time at home.
- Published
- 2002
35. Skin prick test response to enzyme enolase of the baker's yeast (Saccharomyces cerevisiae) in diagnosis of respiratory allergy.
- Author
-
Nittner-Marszalska M, Wójcicka-Kustrzeba I, Bogacka E, Patkowski J, and Dobek R
- Subjects
- Adult, Animals, Asthma immunology, Candida albicans immunology, Feathers immunology, Female, Humans, Hypersensitivity, Immediate immunology, Male, Mites immunology, Pollen immunology, Saccharomyces cerevisiae enzymology, Skin Tests, Allergens, Phosphopyruvate Hydratase immunology, Respiratory Hypersensitivity immunology, Saccharomyces cerevisiae immunology
- Abstract
Background: The aim of the study is to prove that Saccharomyces cerevisiae enolase, the major allergen of the baker's yeast, induces allergic immediate response in patients with inhalant allergy sensitized to Candida albicans extract., Material and Methods: The study was performed in three groups of patients: I. 20 atopic patients with respiratory allergy sensitized to Candida albicans and inhalant allergens (mite, feather, pollens) II. 30 patients with respiratory allergy, positive skin tests to inhalant allergens but negative skin tests to Candida albicans and other fungi; III. 20 nonatopic, healthy individuals. Skin prick test of purified enolase from Saccharomyces cerevisiae (bakers yeast) at concentration 1 and 10 mg/ml was performed in all groups. The results were documented planimetrically., Results: 95% of patients sensitized to Candida albicans extract showed positive skin reactions to Saccharomyces cerevisiae enolase, 10% of patients of group II and none of the patients of the control group had positive skin responses to enolase. The mean wheal size (mm2) in skin prick test to Candida albicans, Saccharomyces cerevisiae enolase at concentration 10 mg/ml was x = 15.17 +/- 11.08, 15.76 +/- 19.67 and at concentration 1 mg/ml 10.02 +/- 10.49, respectively., Conclusions: 1. Saccharomyces cerevisiae enolase induces an immediate allergic reaction in skin in subjects with respiratory allergy and positive skin prick test results to Candida albicans and other fungi. 2. Enolase can be an important allergenic component of the Candida albicans extract.
- Published
- 2001
36. [Sick building syndrome: three case reports].
- Author
-
Bogacka E
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Motor Vehicles, Occupational Diseases diagnosis, Sick Building Syndrome diagnosis
- Abstract
SBS--sick building syndrome--is a set multi-organ symptoms related to long-term staying in "sick buildings". These are modern, energy saving, air tight buildings with reduced ventilation. As a result of such construction, harmful, air-borne substances issued by interior decoration materials, air-conditioning systems and working people are cumulated. The study presents three cases of allergic patients whose original allergic illnesses got aggravated as an effect of: 1) staying in a freshly redecorated room, 2) staying in a fully air-conditioned room, 3) long-term exposition to bacteria and fungi allergens developing in old, used up filters of a car air-condition system.
- Published
- 1999
37. [Decongestants in treatment of nasal obstruction].
- Author
-
Bogacka E
- Subjects
- Adrenergic alpha-Agonists therapeutic use, Female, Humans, Nasal Obstruction etiology, Phenylephrine, Pregnancy, Pregnancy Complications drug therapy, Pulmonary Ventilation drug effects, Rhinitis complications, Sympathomimetics therapeutic use, Nasal Decongestants therapeutic use, Nasal Obstruction drug therapy, Rhinitis drug therapy
- Abstract
Decongestants have long been used in nose obstruction. On the one hand they seem to be abused in local treatment, on the other they are too rarely used in initial treatment of other pathological states of the nose. Yet, as the knowledge of the nasal mucosa vascular system and its neurological and humoral regulation increases, there appear broader indications for their application. A more frequent use of the drugs could be suggested in infectious and allergic rhinitis and paranasal sinusitis, where their application prevents complications and enhances the efficacy of treatment. The sympathomimetic drugs are recommended in rhinitis because a reduction of nasal congestion permits the introduction of other topical therapy such as nasal corticosteroids. They are also recommended in rhinitis during pregnancy and diagnostic procedures in some cases of structural rhinitis. This article briefly discusses the relationships between the nasal mucosa vascular system, the autonomic nervous system and neuropeptides in the regulation of air flow in the nose. Regarding their use in rhinitis treatment, there were characterized groups of sympathomimetic vasoconstrictor agents, which include sympathicomimetics (e.g. phenylpropandamine, phenoloephedrine) and alpha-receptor agonist medications (e.g. xylometazoline, oxymetazoline, naphazoline). The author discussed the pathomechanism of rhinitis medicamentosa resulting from abuse of nasal drops containing alpha-agonists and suggested a therapy.
- Published
- 1999
38. [Intolerance to hydrocortisone in two patients with bronchial asthma].
- Author
-
Bogacka E, Małolepszy J, Suchnicka R, and Dawidiuk I
- Subjects
- Adult, Drug Hypersensitivity diagnosis, Female, Humans, Middle Aged, Asthma drug therapy, Hydrocortisone adverse effects
- Abstract
One patients with nonatopic aspirin-sensitive asthma and another one with atopic asthma responding favourably to aspirin with a history of hydrocortisone intolerance were examined. The patients were challenged with intravenous, inhaled and oral hydrocortisone and its solvent. They showed significant fall of FEV1 after provocation tests with hydrocortisone but not after the solvent. Intradermal skin testing performed with hydrocortisone and its solvent was negative, what suggests that the intolerance to hydrocortisone was probably nonallergic feature. The patients tolerated well the intravenous challenge with prednisolone and oral challenge with prednisone, prednisolone and betamethasone. We suggest the replacement of intravenous hydrocortisone with these corticosteroids in the treatment of patients with hydrocortisone intolerance.
- Published
- 1994
39. [Diurnal rhythm of plasma cortisol in bronchial asthma].
- Author
-
Bogacka E
- Subjects
- Circadian Rhythm, Humans, Asthma blood, Hydrocortisone blood
- Published
- 1981
40. [Diurnal rhythm of plasma cortisol in ulcerative colitis].
- Author
-
Kuczyńska-Sekieta K, Małolepszy J, Bogacka E, and Machaj Z
- Subjects
- Adult, Circadian Rhythm, Humans, Middle Aged, Colitis, Ulcerative blood, Hydrocortisone blood
- Published
- 1981
41. [Diurnal rhythm of plasma cortisol in patients with bronchial asthma on long-term treatment with adrenocorticosteroids].
- Author
-
Bogacka E
- Subjects
- Asthma blood, Circadian Rhythm, Humans, Prednisone administration & dosage, Time Factors, Asthma drug therapy, Hydrocortisone blood
- Published
- 1981
42. [A case of lethal splenic hemorrhage in the course of primary biliary cirrhosis of the liver].
- Author
-
Zapaśnik L and Bogacka E
- Subjects
- Female, Humans, Middle Aged, Hemorrhage etiology, Liver Cirrhosis, Biliary complications, Splenic Infarction etiology
- Published
- 1969
43. [Coxsackie B-3 virus infection in 2-week-old mice. I. Cardiac changes].
- Author
-
Niznikowska-Marks MJ, Bogacka E, and Woźniewicz B
- Subjects
- Age Factors, Animals, Guinea Pigs, Heart microbiology, Mice, Mice, Inbred Strains, Coxsackievirus Infections pathology, Myocarditis etiology, Myocardium pathology
- Published
- 1973
44. [Thick-bile syndrome following infectious icterus].
- Author
-
Hroboni T, Zalewski T, Winnicki S, and Bogacka E
- Subjects
- Child, Preschool, Cholestasis surgery, Hepatomegaly complications, Humans, Liver Cirrhosis pathology, Male, Prognosis, Bile, Cholestasis complications, Hepatitis A complications
- Published
- 1971
45. [Double pelvo-ureteral system. Selected problems].
- Author
-
Niznikowska-Marks J, Oknińska A, Wróblewska-Cieliszak K, and Bogacka E
- Subjects
- Abnormalities, Multiple complications, Age Factors, Child, Preschool, Female, Humans, Infant, Kidney pathology, Kidney Diseases pathology, Male, Sex Factors, Kidney Pelvis abnormalities, Ureter abnormalities
- Published
- 1972
46. [Hepatic changes in mucoviscidosis].
- Author
-
Bogacka E, Newecka T, and Zalewski T
- Subjects
- Autopsy, Bile Ducts, Intrahepatic physiopathology, Female, Hepatomegaly, Humans, Infant, Infant, Newborn, Male, Time Factors, Cystic Fibrosis pathology, Liver pathology
- Published
- 1971
47. [Edematous form of mucoviscidosis].
- Author
-
Zalewski T, Bogacka E, and Pulwarska E
- Subjects
- Autopsy, Bronchi pathology, Female, Humans, Infant, Infant, Newborn, Male, Pancreas pathology, Cystic Fibrosis pathology, Edema pathology
- Published
- 1973
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.